Merck's Isentress gets EU nod for HIV label expansion
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended that Merck & Co's HIV integrase inhibitor Isentress (raltegravir) be granted a label expansion to include treatment-naïve patients.